Anti-nectin-4-antibodies and uses thereof

Patent metadata

Field	Value
Publication number	US-12049500-B2
Application number	US-202218263430-A
Country	US
Kind code	B2
Filing date	Mar 31, 2022
Priority date	Mar 31, 2021
Publication date	Jul 30, 2024
Grant date	Jul 30, 2024

Abstract

The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.

First claim

The invention claimed is:

1. A monoclonal antibody or antigen-binding fragment thereof which binds to Nectin-4 comprising
(a) a variable heavy chain (VH) region comprising complementarity-determining regions (CDRs) CDR-H1, CDR-H2 and CDR-H3, wherein
(i) the CDR-H1 comprises an amino acid sequence according to SEQ ID NO: 7,
(ii) the CDR-H2 comprises an amino acid sequence according to SEQ ID NO: 8,
(iii) the CDR-H3 comprises an amino acid sequence according to SEQ ID NO: 9,
and

(b) a variable light chain (VL) region comprising complementarity-determining regions (CDRs) CDR-L1, CDR-L2 and CDR-L3, wherein
(i) the CDR-L1 comprises an amino acid sequence according to SEQ ID NO: 10,
(ii) the CDR-L2 comprises an amino acid sequence according to SEQ ID NO: 11,
(iii) the CDR-L3 comprises an amino acid sequence according to SEQ ID NO: 12.

2. The antibody or antigen-binding fragment of claim 1 comprising
(a) a VH region comprising an amino acid sequence according to SEQ ID NO: 13 or an amino acid sequence having an identity thereof of at least 85%, at least 90%, at least 95% or at least 99%, and
(b) a VL region, particularly a VL region comprising an amino acid sequence according to SEQ ID NO:14 or an amino sequence having an identity thereof of at least 85%, at least 90%, at least 95% or at least 99%.

3. The antibody or antigen-binding fragment of claim 1 , which is a chimeric antibody, a multispecific antibody, a bispecific antibody, a human antibody, a humanized antibody or an antigen-binding fragment thereof.

4. The antibody or antigen-binding fragment of claim 1 , which is an antibody of class IgG, of class IgM, of class IgA or an antigen-binding fragment thereof, or which is a single-chain antibody, or an antibody Fv fragment.

5. A human or humanized monoclonal antibody or antigen-binding fragment thereof which binds to Nectin-4 comprising
(a) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 27,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 28, or

(b) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 42, or

(c) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or

(d) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or

(e) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 56, or

(f) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 41,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or

(g) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 55,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 70 or 103, or

(h) (i) a VH region comprising an amino acid sequence according to SEQ ID NO: 69,
and
(ii) a VL region comprising an amino acid sequence according to SEQ ID NO: 56.

6. The antibody or fragment of claim 1 in combination with a carrier or excipient suitable for use in medicine.

7. The antibody or fragment of claim 1 in combination with a carrier suitable for administration to a subject suffering from or likely to suffer from cancer associated with Nectin-4 overexpression.

8. A nucleic acid coding for one or more antibodies according to claim 1 , or for at least one VL and/or one VH of said antibodies.

9. A vector comprising the nucleic acid according to claim 8 .

10. A host cell comprising the vector of claim 9 .

11. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to claim 1 .

12. The antibody or antigen-binding fragment of claim 4 , wherein said antibody of class IgG, has a subclass selected from the group consisting of IgG1, IgG2, IgG3 and IgG4.

13. The antibody or fragment of claim 6 , wherein said carrier or excipient is suitable for therapeutic or diagnostic applications.

14. The antibody or fragment of claim 13 , wherein said diagnostic applications include in vitro and in vivo diagnostic applications.

15. The antibody or antigen-binding fragment of claim 1 , wherein said antibody is a chimeric antibody or an antigen-binding fragment thereof.

16. The antibody or antigen-binding fragment of claim 1 , wherein said antibody is a humanized antibody or an antigen-binding fragment thereof.

17. The antibody or antigen-binding fragment of claim 1 , wherein said antibody is an antibody of subclass IgG1 or an antigen-binding fragment thereof.

18. The antibody or antigen-binding fragment of claim 1 , wherein said antibody is an antibody of subclass IgG2 or an antigen-binding fragment thereof.

19. The antibody or antigen-binding fragment of claim 1 , wherein said antibody is an antibody of subclass IgG3 or an antigen-binding fragment thereof.

20. The antibody or antigen-binding fragment of claim 1 , wherein said antibody is an antibody of subclass IgG4 or an antigen-binding fragment thereof.

Assignees

• Emergence Therapeutics Gmbh
• Univ Aix Marseille
• Inst Nat Sante Rech Med
• Inst Jean Paoli & Irene Calmettes
• Centre National De La Rech Scientifique—Cnrs

Inventors

• Elands Jack
• L'Hospice Florence
• Préville Xavier
• Olive Daniel
• Lopez Marc

Classifications

• C07K2317/92

  Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title

• C07K2317/77

  Internalization into the cell · CPC title

• C07K2317/71

  Decreased effector function due to an Fc-modification · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61K2039/505

  comprising antibodies · CPC title